Navigation Links
NeuroPhage, Inc. Raises $6.4 Million In Additional Financing
Date:5/6/2013

CAMBRIDGE, Mass., May 6, 2013 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round. Merieux Developpement led the financing with participation from all current Neurophage investors, including Shire LLC. The new funds will help support ongoing pre-IND studies for lead compound NPT002 and will advance the development of second-generation fusion proteins with the potential for treating several neurodegenerative conditions including Alzheimer's, Parkinson's and Huntington's diseases. Separately, NeuroPhage announced that current Director John F. Dee has been named Chairman of the Board and Kenneth A. Buckfire has joined as a Director.

"We are encouraged by NeuroPhage's progress in further elucidating the mechanism of action of NPT002 and advancing the program toward clinical trials, as well as its discovery of new antibody-like fusion proteins with the potential to broadly address neurodegenerative disease markets with enormous unmet need," said Dr. Valerie Calenda , Partner at Merieux Developpement. "We believe the company's transformative approach to addressing protein misfolding could make a major contribution to achieving greatly improved treatments for these disabling conditions that affect millions of people worldwide."

Deposits of misfolded proteins in the brain are associated with many neurodegenerative diseases.  NPT002 has demonstrated the ability to safely and effectively mediate clearance of misfolded protein deposits (including amyloid-beta, tau and alpha-synuclein) in multiple animal models of neurodegenerative disease, resulting in cognitive and behavioral improvements. Following a successful pre-IND meeting with the FDA, NeuroPhage is conducting pre-IND safety studies and scaling-up cGMP manufacturing activities to support a planned IND filing next year. 

"This supplemental financing demonstrates the continued confidence of our investors in the promise of our scientific platform targeted at neurodegenerative diseases," said Jonathan Solomon , President and Chief Executive Officer of NeuroPhage. "We believe that the unique ability of our drug candidates to target multiple neurotoxic protein aggregates in the brain represents a breakthrough approach to slowing or preventing the devastating progression of neurodegenerative diseases."

NeuroPhage scientists have recently shown that the NPT002 mechanism of action is based on a novel general amyloid interaction motif (GAIM).  Motifs define distinctive and recurring components of protein structure and interaction that can have biological significance. The discovery of GAIM has allowed the creation of new antibody-like fusion proteins that have the broad neurodegenerative disease-targeting ability of NPT002.

In connection with the financing, NeuroPhage announced that John F. Dee has been named Chairman and Kenneth A. Buckfire has joined the Board as a Director. Mr. Dee brings a wealth of industry experience as the former CEO of several successful neuroscience-focused biotechnology companies that were acquired by major pharmaceutical firms. Mr. Buckfire brings extensive strategic and financial experience as Vice Chairman of Stifel Investment Banking and President of Miller Buckfire & Company, a Stifel Company.

Solomon added, "We welcome John Dee as Chairman and Ken Buckfire as a new board member.  We expect their extensive experience in financing and growing successful biotechnology companies will be invaluable as we advance our unique product pipeline toward clinical testing."About NeuroPhageNeuroPhage is a pioneering biotechnology company, located in Cambridge, MA, whose mission is to advance the treatment of chronic neurodegenerative diseases associated with protein misfolding, including Alzheimer's and Parkinson's diseases. The company is applying its unique technology platform to develop a pipeline of drug candidates consisting of broadly acting agents that simultaneously reduce levels of multiple pathogenic protein aggregates in the brain. This technology should provide significant therapeutic advantages over single target approaches and has broad applications for treating Alzheimer's disease, Parkinson's disease, and other indications associated with protein pathologies of the CNS. The company was founded in 2007 by a Cambridge-based team, together with inventor Professor Beka Solomon , Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University. More information can be found at: www.neurophage.com.About Merieux DeveloppementMerieux Developpement is the private equity arm of the French group, Institut Merieux, which has 12,000 employees worldwide and generated revenues of EUR 1.7B in 2011. Merieux Developpement invests in the healthcare sector on a global basis, working alongside entrepreneurs whose products and services can bring genuine advances to the health of patients and consumers worldwide, offering them access to its industry expertise and global network. More information can be found at: www.merieux-developpement.com.

About Shire
Shire enables people with life-altering conditions to lead better lives. Through our deep understanding of patients' needs, we develop and provide healthcare in the areas of: Behavioral Health and Gastro Intestinal conditions, Rare Diseases, Regenerative Medicine as well as other symptomatic conditions treated by specialist physicians. We aspire to imagine and lead the future of healthcare, creating value for patients, physicians, policymakers, payors and our shareholders. More information can be found at: www.shire.com.Contacts:Neurophage, Inc.

MediaJonathan Solomon

BLL Partners, LLC President and CEO

Barbara Lindheim (617) 714-4940

(212) 584-2276 jsolomon@neurophage.com

blindheim@bllbiopartners.com


'/>"/>
SOURCE NeuroPhage Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Minimally Invasive Devices Raises $9 Million in Series B Financing to Commercialize Laparoscopic Visualization Product
2. PCMA: New Report Shows Drugstore Lobby Agenda Raises Rx Costs for Small Businesses, Government Programs
3. Promotion Raises Awareness of Scar Treatment
4. MacuLogix Raises $3.6 Million in Series A Round
5. Leader In At-Home Laboratory Testing Praises Federal Panels Recommendations For Widespread HIV Testing
6. Cardioxyl Pharmaceuticals Raises $28 Million In Series B Financing Led By OrbiMed Advisors
7. Bayers Second Annual Virtual Walk for Hemophilia Raises Funds, Generates Excitement in the Hemophilia Community
8. Perrigo Reports Record First Quarter Revenue And Adjusted Earnings And Raises Full Year Adjusted EPS Guidance
9. Elekta Raises $52,200 to Support Individuals with Cancer
10. Cardinal Health Board Of Directors Raises Quarterly Dividend
11. BiO2 Medical Raises $12M in Series C Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ReportsnReports.com adds "Pulmonary Arterial ... report that provides an overview of the PAH ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Pulmonary Arterial ...
(Date:4/28/2016)... 28, 2016   Click here for supplemental ... (NYSE: DPLO), the nation,s largest independent specialty pharmacy, ... agreement to acquire Valley Campus Pharmacy, Inc., doing ... leading specialty pharmacy that provides individualized patient care, ... . In 2015, TNH generated approximately $400 million ...
(Date:4/28/2016)... April 28, 2016  The blood testing market in ... according to Kalorama Information and The Freedonia Group in ... nucleic acid testing.  The healthcare research firm said that ... developing blood collection stations and in improving testing at ... Information,s report, Blood Testing Market in China ...
Breaking Medicine Technology:
(Date:5/1/2016)... Mission Viejo, CA (PRWEB) , ... May 01, 2016 , ... ... plan for those in need of chiropractic help. The agency offers a verity of ... and any chiropractic need. According to Chris Nelson at the firm, “Many insurance plans ...
(Date:4/30/2016)... ... 30, 2016 , ... The Hacking Medicine Institute ... critically evaluate and rank health-focused applications and connected devices for better disease monitoring ... and accurate information to help accelerate patient and provider adoption of clinically proven ...
(Date:4/30/2016)... ... 2016 , ... “Aging well is a challenge for all of us, but there are things we can do ... . “Research is showing more and more that there are simple, yet important steps that ... we age.” Top priorities Dr. Kohli’s recommends for her patients include;, , ...
(Date:4/29/2016)... ... April 29, 2016 , ... In an article ... shares her enthusiasm for Botox and lip injections, which she underwent in order to ... Coachella Valley Music and Arts Festival. The article explains that Ms. Mirmelli’s situation is ...
(Date:4/29/2016)... ... 2016 , ... Our bodies are bombarded daily by environmental and lifestyle factors ... stressors is to adopt a more healthful diet, but too many people think that ... Holistic Nutritionist and the creator of the Newport Beach Cleanse and 14-Day Eating Plan, ...
Breaking Medicine News(10 mins):